The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer

Angiogenesis, a hallmark of cancer, plays a fundamental role in colorectal cancer (CRC). Anti-angiogenic drugs and chemotherapy represent a standard of care for treating metastatic disease. Immune checkpoint inhibitors (ICIs) have changed the therapeutic algorithm of many solid tumors. However, the...

Full description

Bibliographic Details
Main Authors:	Brigida Anna Maiorano, Alessandro Parisi, Evaristo Maiello, Davide Ciardiello
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Series:	Life
Subjects:	colorectal cancer CRC anti-angiogenics angiogenesis immune checkpoint inhibitors ICIs
Online Access:	https://www.mdpi.com/2075-1729/12/10/1552

Similar Items

How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review
by: Brigida Anna Maiorano, et al.
Published: (2022-04-01)

Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day
by: Brigida Anna Maiorano, et al.
Published: (2022-02-01)

Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
by: Lei Wang, et al.
Published: (2024-01-01)

Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application
by: An‐Qi Li, et al.
Published: (2024-01-01)

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
by: Yipeng Song, et al.
Published: (2021-02-01)

Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience
by: Paola Parente, et al.
Published: (2022-03-01)

Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
by: Rui He, et al.
Published: (2021-11-01)

Differential action of pro-angiogenic and anti-angiogenic components of Danhong injection in ischemic vascular disease or tumor models
by: Shuang He, et al.
Published: (2022-01-01)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
by: Liting Zhong, et al.
Published: (2021-05-01)

Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies
by: Changyu Yao, et al.
Published: (2023-01-01)

Homeostatic Regulation of Pro-Angiogenic and Anti-Angiogenic Proteins via Hedgehog, Notch Grid, and Ephrin Signaling in Tibial Dyschondroplasia
by: Shah Nawaz, et al.
Published: (2023-12-01)

Preclinical Evaluation of a Novel Small Molecule LCC-21 to Suppress Colorectal Cancer Malignancy by Inhibiting Angiogenic and Metastatic Signatures
by: Ntlotlang Mokgautsi, et al.
Published: (2023-01-01)

bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
by: Gehan Xu, et al.
Published: (2022-10-01)

Significance of anti-angiogenic therapy in head and neck cancer—Heterogeneity of tumor endothelium
by: Kyoko Hida, et al.
Published: (2010-02-01)

Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer
by: Luka Roškar, et al.
Published: (2021-12-01)

Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series
by: Luigi Liguori, et al.
Published: (2023-11-01)

Endoglin (CD105) and VEGF as potential angiogenic and dissemination markers for colorectal cancer
by: Ana Nogués, et al.
Published: (2020-05-01)

Immunotherapies catering to the unmet medical need of cold colorectal cancer
by: Jun Yuan, et al.
Published: (2022-10-01)

Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy
by: Mineyoshi Sato, et al.
Published: (2023-04-01)

Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States
by: Marion Ferreira, et al.
Published: (2021-06-01)

An Insight into the Anti-Angiogenic and Anti-Metastatic Effects of Oridonin: Current Knowledge and Future Potential
by: Nurul Akmaryanti Abdullah, et al.
Published: (2021-02-01)

Nonlinear Adaptive Optimal Controller Design for Anti-Angiogenic Tumor Treatment
by: Nitendra Nath, et al.
Published: (2023-02-01)

Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia
by: Daniela S. Ardelean, et al.
Published: (2015-02-01)

Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer
by: Yingying Li, et al.
Published: (2022-03-01)

Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy
by: Lars M. Schiffmann, et al.
Published: (2022-05-01)

AntAngioCOOL: computational detection of anti-angiogenic peptides
by: Javad Zahiri, et al.
Published: (2019-03-01)

Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer
by: Lin A, et al.
Published: (2023-04-01)

Sensitivity analysis unveils the interplay of drug-sensitive and drug-resistant Glioma cells: Implications of chemotherapy and anti-angiogenic therapy
by: Latifah Hanum, et al.
Published: (2024-01-01)

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma
by: Stephane Oudard, et al.
Published: (2021-12-01)

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine
by: Chao Mei, et al.
Published: (2023-03-01)

Anti-angiogenic therapy for glioma: Puzzle and hope
by: Zhong-ping Chen
Published: (2019-01-01)

Long-term survival with a combination of immunotherapy, anti-angiogenesis, and traditional radiotherapy in brain metastatic small cell lung cancer: a case report
by: Yan-yan Long, et al.
Published: (2023-10-01)

Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis
by: Monica S. Chung, et al.
Published: (2022-04-01)

Thrombus leukocytes exhibit more endothelial cell-specific angiogenic markers than peripheral blood leukocytes do in acute coronary syndrome patients, suggesting a possibility of trans-differentiation: a comprehensive database mining study
by: Hangfei Fu, et al.
Published: (2017-03-01)

IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma
by: Mimma Rizzo, et al.
Published: (2022-08-01)

Effect of novel anti-tumor and anti-angiogenesis drug taurolactone on angiogenic factor AGGF1 and angiogenesis mimicry in patients with hepatocellular carcinoma
by: Shaoping Liu, et al.
Published: (2024-05-01)

Editorial: CD4+ T Cells in Cancer Immunotherapies
by: José M. González-Navajas, et al.
Published: (2021-09-01)

The role of the gut microbiota in tumor, immunity, and immunotherapy
by: Yuyan Xie, et al.
Published: (2024-06-01)

Combining spatially fractionated radiation therapy (SFRT) and immunotherapy opens new rays of hope for enhancing therapeutic ratio
by: Qiuxia Lu, et al.
Published: (2024-01-01)

Predictive biomarkers of colon cancer immunotherapy: Present and future
by: Wanting Hou, et al.
Published: (2022-11-01)